Maximum Intravenous Dose of Levetiracetam (Keppra)
The maximum recommended daily dose of IV levetiracetam for adults is 3000 mg/day (1500 mg twice daily), with no evidence that higher doses confer additional benefit. 1
Standard Dosing Parameters
Adults (≥16 years)
- Maximum daily dose: 3000 mg/day administered as 1500 mg twice daily 1
- Initial dosing: 1000 mg/day (500 mg twice daily) 1
- Dose escalation: May increase by 1000 mg/day every 2 weeks up to maximum 1
- Loading doses for status epilepticus: Up to 60 mg/kg (maximum 4500 mg single dose) have been studied, though FDA labeling does not explicitly endorse this 2
Pediatric Populations
- Ages 4-16 years: Maximum 60 mg/kg/day (not to exceed 3000 mg/day) 1
- Ages 6 months-4 years: Maximum 50 mg/kg/day 1
- Ages 1-6 months: Maximum 42 mg/kg/day 1
Status Epilepticus Context
For benzodiazepine-refractory status epilepticus, levetiracetam 40-60 mg/kg IV bolus (maximum 2500-4500 mg) is commonly used based on guideline recommendations and clinical practice, though this exceeds the FDA-approved maintenance dosing. 2
- Pediatric status epilepticus protocols recommend 40 mg/kg (maximum 2500 mg) IV bolus 2
- Adult emergency guidelines support levetiracetam, fosphenytoin, or valproate as equivalent second-line agents after benzodiazepines 2
- Studies have evaluated single doses of 2500-4500 mg for status epilepticus with acceptable safety profiles 2
Renal Dose Adjustments
Dosing must be reduced in renal impairment, with maximum doses ranging from 500-1000 mg every 24 hours in end-stage renal disease. 1
- Mild impairment (CrCl 50-80): Maximum 1000 mg every 12 hours 1
- Moderate impairment (CrCl 30-50): Maximum 750 mg every 12 hours 1
- Severe impairment (CrCl <30): Maximum 500 mg every 12 hours 1
- ESRD on dialysis: 500-1000 mg every 24 hours with 250-500 mg supplemental dose post-dialysis 1
Safety Considerations
The FDA label explicitly states "there is no evidence that doses greater than 3000 mg/day confer additional benefit" for chronic epilepsy management. 1
However, recent research demonstrates that rapid IV push administration of undiluted levetiracetam in loading doses up to 4500 mg is well-tolerated, with minimal adverse events limited primarily to injection site reactions 3, 4. Hypotension occurs in approximately 9% of patients receiving high-dose (≥3000 mg) IV push levetiracetam, though confounding medications often contribute 5.
Common Pitfalls
- Do not exceed 3000 mg/day for maintenance therapy without clear justification, as efficacy plateaus and no additional benefit has been demonstrated 1
- Avoid abrupt discontinuation to reduce risk of increased seizure frequency and status epilepticus 1
- Monitor for behavioral abnormalities and psychotic symptoms, which occur in 13% of adults and 38% of pediatric patients 1
- Adjust for renal function using calculated creatinine clearance adjusted for body surface area 1